EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), & Global Clinical Development and Medical Affairs at Santen today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for sirolimus (DE-109) for the treatment of chronic/refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis, and non-infectious uveitis affecting the posterior segment of the eye. The designation follows the granting of orphan drug status by the European Commission in September 2011. “This is an important milestone in the development of sirolimus for non-infectious uveitis affecting the posterior segment of the eye,” said Toshiaki Nishihata, Ph.D., Director, Executive Corporate Officer U.S. and Europe Business, and Head of Research and Development Division at Santen Inc.
